- Home
- DSP vs NVCT Comparison
DSP vs NVCT Comparison
Compare DSP & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSP | NVCT |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 220.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DSP | NVCT |
|---|---|---|
| Price | $12.41 | $8.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $18.11 | $15.33 |
| AVG Volume (30 Days) | ★ 188.5K | 44.2K |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $344,201,000.00 | N/A |
| Revenue This Year | $16.52 | N/A |
| Revenue Next Year | $16.62 | N/A |
| P/E Ratio | $35.00 | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.11 | $5.55 |
| 52 Week High | $16.25 | $11.52 |
Technical Indicators
Market Signals| Indicator | DSP | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 68.06 | 52.62 |
| Support Level | $12.32 | $8.01 |
| Resistance Level | $13.20 | $9.20 |
| Average True Range (ATR) | 0.79 | 0.42 |
| MACD | 0.37 | -0.00 |
| Stochastic Oscillator | 85.08 | 47.02 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.